Putting this study in a larger perspective, enhanced generation of the anaphylatoxin C5a may not only moderate apoptotic events in the in vitro setting or extreme setting of polytrauma but also in other diseases such as infections, ischemia (e.g., myocardial infarction or stroke), neurodegenerative diseases, and even in cancer, because in all these conditions, a local or systemic complement activation has been described [38,39]. The gene discussed is C5; the disease is ischemia.